Francis KE, Kim SI, Friedlander M, Gebski V, et al. The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. Ann Oncol 2022 Feb 24. pii: S0923-7534(22)00338.
PMID: 35219776